The Role of the Hypoxia-Related Unfolded Protein Response (UPR) in the Tumor Microenvironment

Simple Summary The complex signaling networks that different cancers utilize for cell survival remain poorly understood. A major problem is the complexity of the tumor microenvironments (TME). Here, we discuss the role of intermittent hypoxia as one of the inducers of the UPR in the TME and the related implications of it for both cancer progression and therapeutic approaches. Abstract Despite our understanding of the unfolded protein response (UPR) pathways, the crosstalk between the UPR and the complex signaling networks that different cancers utilize for cell survival remains to be, in most cases, a difficult research barrier. A major problem is the constant variability of different cancer types and the different stages of cancer as well as the complexity of the tumor microenvironments (TME). This complexity often leads to apparently contradictory results. Furthermore, the majority of the studies that have been conducted have utilized two-dimensional in vitro cultures of cancer cells that were exposed to continuous hypoxia, and this approach may not mimic the dynamic and cyclic conditions that are found in solid tumors. Here, we discuss the role of intermittent hypoxia, one of inducers of the UPR in the cellular component of TME, and the way in which intermittent hypoxia induces high levels of reactive oxygen species, the activation of the UPR, and the way in which cancer cells modulate the UPR to aid in their survival. Although the past decade has resulted in defining the complex, novel non-coding RNA-based regulatory networks that modulate the means by which hypoxia influences the UPR, we are now just to beginning to understand some of the connections between hypoxia, the UPR, and the TME.


Introduction
The tumor microenvironment (TME) is a dynamic network that is created by blood vessels, lymphatic vessels, fibroblasts, immune cells as well as components such as the extracellular matrix (ECM) [1,2] that establishes a "friendly ecosystem" for cancer cells. Since tumors and the selective conditions that are present in the TME influence each other to either promote or to repress cancer progression, understanding the molecular pathways governing these interactions may contribute to the development of novel therapies. During rapid tumor progression, cancer cells are often dealing with hypoxic conditions that are caused a limited blood supply [3,4]. Hypoxia induces a cellular adaptive response that elevates the expression of the transcription factors called hypoxia-inducible factors (HIFs) that activate the global gene expression changes in both non-malignant and cancer cells. HIF-1 and HIF-2 promote increases in the lymphangiogenic and angiogenic responses as well as metabolic changes that lead to a shift to glycolysis [5][6][7][8][9][10][11][12][13][14]. While these transcriptional changes enhance the tumor growth and viability, they also offer potential targets for new cancer therapeutic strategies [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29]. oxidase (COX) subunit composition expression [94,95], and this is accompanied by a HIFelevated expression of carbonic anhydrase 9 (CA-IX) and monocarboxylate transporter 4 (MCT4) that prevent the acidosis as a consequence of glycolysis-related proton release [96,97]. These glycolytic changes result in a lower ATP production, and the cellular energy requirements are limited by a HIF-mediated selective translational blockage [98][99][100]. This also promotes the induction of autophagy and mitophagy [100][101][102][103] by an-mTOR independent pathway [31,104].
During this glycolytic switch, the cellular ATP-dependent processes such as protein synthesis, disulfide-bonds formation, peptide folding, and the maintenance of the redox potential and ion homeostasis are limited [49,105]. Furthermore, the hypoxia-related metabolic switch increases the production of lactic acid, thereby resulting in acidosis, the deregulation of intracellular calcium levels, and the overproduction of reactive oxygen species (ROS) [106][107][108]. Limited the glucose and glutamine demands would reduce the synthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) and thereby, limit the N-linked glycosylation in ER [109] as well as deregulate the ER calcium influx [110]. Furthermore, the changes in mitochondrial activity would result in the intracellular accumulation of ROS [111] since high amounts of ROS are generated as a byproduct of fatty acid β-oxidation [112][113][114]. Some of the TME deregulated cytokines and growth factors have also been reported to activate the NADPH oxidases and contribute to the ROS accumulation [45]. Finally, a prolonged hypoxia disturbs the protein import processes in the mitochondria as well as mitochondrial protein folding, and this activates the mitochondrial unfolded protein response (UPRmt) [115][116][117][118]. Hence, hypoxia, along with all these other factors, can deregulate the cellular proteostasis and consequently activate the UPR. This results in a complex molecular network of interactions that affect the TME, and consequently, the tumor's progression ( Figure 1). Figure 1. The hypoxia-related deregulation of ER homeostasis in TME cells that can result in activation of the UPR and UPRmt and subsequently modulate TME.
Although HIF complexes containing HIF-1α subunits are considered to be the principal mediators of the cellular responses to hypoxia, in specific tissues, their functions can be supported and extended by the complexes that are formed by other α isoforms that include HIF-2α and HIF-3α [9,14,[119][120][121][122][123][124]. The HIF-dependent transcriptional Figure 1. The hypoxia-related deregulation of ER homeostasis in TME cells that can result in activation of the UPR and UPRmt and subsequently modulate TME.
Hypoxia is only one of numerous processes that can induce an ER stress, and other ways include a nutrient deprivation, acidosis, a high metabolic demand, the processes of reactive oxygen species, an augmented secretory capacity, the deregulation of transcription and translation, and therapies that are related to the impact of cytotoxic drugs and radiation [45]. Depending on the specific pathological conditions of the TME, the involvement of UPR activation and the magnitude of this response may differ significantly. For example, the TME cells can utilize these signaling pathways for adaption and survival or they can lead to autophagy or apoptosis.

The UPR and UPRmt
The occurrence of an ER stress increases the demand for chaperones in the lumen of this organelle, and this leads to UPR initiation which begins with the glucose-regulated protein 78 (GRP78 also known as BiP (binding immunoglobin protein)) release from the luminal domains of three ER transmembrane sensors: protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme 1α (IRE1α), and activating transcription factor 6 (ATF6) [37,42]. BiP dissociation activates PERK and IRE1α via multimerization and trans-autophosphorylation, and this allows the ATF6 proteolytic maturation into an active ATF6f (p50) transcription factor to occur [138][139][140]. Upon their activation, all of these proteins initiate signaling pathways that function to help the cells to adapt to this insult, to repair the damage, and to restore ER homeostasis [141]. The ATF6f promotes the synthesis of the protein chaperones (including BiP) and the ER membrane lipids, the ER-associated degradation (EDEM) of the misfolded proteins, and it enhances N-glycosylation [142,143]. IRE1α is also responsible for IRE1-dependent decay (RIDD) that degrades selected mRNAs in order to reduce the ER load [144][145][146][147] as well as IRE1 α splices the mRNA transcript of X-box binding-protein (XBP) transcription factor into its transcriptionally active isoform (XBP1s) [148]. XBP1s promote the ER membrane's biosynthesis and support its folding capacity [9,36,148,149]. The main consequence of PERK activation is the phosphorylation of the alpha subunit of the eukaryotic initiation factor eIF2. This promotes a general suppression of protein synthesis [42,150,151], and it allows for the increased expression of specific proteins including (1) growth arrest and DNA damage inducible protein (GADD34), (2) proapoptotic CCAAT/enhancer binding homologous protein (CHOP), and (3) activating transcription factor 4 (ATF4). ATF4 transcriptionally supports the adaptation to an ER stress and protein folding [152], whereas GADD34 enables the dephosphorylation of eIF2, and thus removes the translational blockage when the ER stress is mitigated [153].
In non-malignant cells, if the UPR stress response is too persistent or too intense, the cell death pathways are initiated. Although the accumulation of ATF4 and the PERKdependent proapoptotic factor CHOP are well recognized as cell death signals, IRE1 can stimulate the Janus N-terminal kinase (JNK) to increase the expression of the death receptor 5 (DR5), and ATF6f can also contribute to the CHOP accumulation [9,144,154,155]. The UPR is also accompanied by complex changes in many other apoptotic proteins such as the p53 upregulated modulator of apoptosis (PUMA), phorbol-12-myristate-13-acetateinduced protein 1 (PMAIP1, also known as NOXA), and growth arrest and DNA damage -inducible alpha GADD45A [141,146,[156][157][158][159], which together with the main signals, influence the cell's fate. Furthermore, the UPR-specific roles of noncoding RNAs also play a role. For example, all of the UPR pathways modulate specific miRNA levels in order to prevent to extensive accumulation of proadaptive or apoptotic proteins [9,44,[160][161][162][163]. Although the intrinsic apoptotic pathway is the main mechanism that is responsible for cell death during the UPR, recent studies indicate that the PERK branch of UPR can lead to autophagy [164,165] and necroptosis [166][167][168][169][170][171]. The activation of the latter pathways in hypoxic conditions prevents the HIF-dependent metabolic switch and thus, this increases the intracellular ROS accumulation [172][173][174][175].
In the TME cancer cells, the UPR-specific signals are often clouded via the oncogenic transformations [45] given that activation of the oncogenes results in an increased protein and membrane synthesis [176]. Furthermore, the cancer cells adapt to avoid the UPR cell death signals as illustrated by the MYC Proto-Oncogene example. Increased levels of this oncogene in normal cells results in apoptosis, whereas in cancers cells, both the XBP1s and IRE1 allow for the cells to avoid an MYC-related cell death [177][178][179]. The IRE1 pathway also modulates some of the effects of the mutant RAS, however, the significance of this for cancer cell survival remains unclear [180].
Finally, the hypoxia-related metabolic switch and the resulting energetic deficiency may disrupt the mitochondrial protein homeostasis and lead to the activation of the mitochondrial UPR (UPRmt). This could occur via the limiting of the influx of the nuclearencoded proteins and interfere with mitochondrial refolding after the protein import and activation of the UPRmt [115][116][117][118]181]. The UPRmt is a proadaptive mechanism that changes the expression of both the mitochondrial and nuclear encoded genes (including ATF5 and ATF4) to restore homeostasis or if this fails, it leads to apoptosis [115][116][117][118]. Notably, the UPRmt-related activation of the PERK pathway has also been reported [115][116][117][118]182].

The Crosstalk between Hypoxia and UPR in the TME
Although the pronounced activation of UPR signaling in cancer has been reported mainly for extreme hypoxic conditions [65,146], numerous reports have indicated that particular aspects of this are triggered even in less oxygen-limiting conditions, including increased BIP expression [33,123,[183][184][185][186][187] and PERK-related activity [73,184,[188][189][190][191][192]. The hypoxia-elevated BiP levels result from the activities of the extracellular signal-regulated kinase (ERK) and protein kinase C (PKC) [184]. Furthermore, the increase in BIP expression can result from the hypoxic induction of its cofactor and transcriptional inducer called the cell migration-inducing and hyaluronan-binding ER protein (CEMIP) [193]. In the ER, CEMIP/GRP78 support the adaptive responses by raising the intracellular calcium levels and subsequently increasing the PKCα activity [193].
Although the PERK-dependent translational attenuation occurs immediately during acute hypoxia, this blockage is removed after a prolonged hypoxic exposure or with increased oxygen levels [188,194,195]. The PERK-related eIF2 phosphorylation is also present in the transient (cyclic hypoxia) models [196][197][198][199][200], and thus, the activation of this branch of UPR is very plausible in solid tumors that are characterized by fluctuating oxygen concentrations during tumor expansion. PERK activation inhibits the HIF-1α translation in cancer cells and thus, limits the HIF-1 transcriptional activity [201].
The transcriptional activity of PERK-preferentially translated ATF4 is limited by PHD1, whereas ATF4 was shown to destabilize PHD3 and thus, support the HIF-1α accumulation [202]. The question of whether this mechanism serves as a buffer of the HIF-1-related cellular adaptation or contributes to cell death will require further research.
Interestingly, the PERK inhibition in hypoxia-exposed cells promotes accelerated cell death [188]. In agreement with these findings, other studies have shown that in several cancer cell lines, PERK signaling is required to stimulate the autophagosome formation through the stimulating transcription of the autophagy genes microtubule-associated protein 1 light chain 3 beta (MAP1LC3B) [46, 74,141]. Furthermore, the PERK activity induces carbonic anhydrase 9 (CA9) and thus, it prevents hypoxia-induced acidosis [106,203], whereas ATF4 activity reduces the hypoxia-related damage and supports maintaining a redox balance and mitochondrial homeostasis [115][116][117][118]182]. Notably, increased ATF4 expression is found in many hypoxic and nutrient-deprived tumors [204], and it has been shown to mediate autophagy under hypoxia [74,205]. PERK and ATF4 have a protective role in oxidative damage in glioblastoma cells that are exposed to cyclic hypoxia or radiotherapy [197,206]. In human cervical cancer, PERK activation during hypoxia results in the accumulation of oncogenic lysosomal-associated membrane protein 3 (LAMP3) and in the increased aggressiveness of these cells [197].
Although PERK activation during hypoxia can lead to increased levels of CHOP expression and cell death in normal cells [179,[207][208][209], in tumors, the CHOP expression is not elevated as dramatically as it is in the pharmacologically induced ER stress [188]. Furthermore, CHOP can also serve in a proadaptive role by limiting the activity of the endothelial nitric synthase (NOS3, eNOS) [210] and preventing the ROS accumulation through the hypoxic uncoupling of this enzyme [44, 211,212].
Despite the fact that the PERK pathway has been considered as the main response pathway of the UPR in hypoxic tumors, the activation of the two other branches occurs as well. The elevated expression of ATF6-dependent prosurvival genes in response to hypoxia has been reported in gastric tumors [213] and mutant p53 cancer cells [214]. Furthermore, the elevated levels of these transcription factors are a hallmark of a poor prognosis for pancreatic cancer patients [16]. The hypoxic activation of ATF6 signaling in the TME, however, has not been convincingly presented so far [188].
Although elevated levels of XBP1s have been reported in many types of cancers and this has been correlated with poor prognosis, the IRE1 activity and the related accumulation of XBP1s has been reported mainly in cells that have been exposed acute and moderate hypoxia [146,188,193,[215][216][217][218][219][220][221]. However, acute hypoxia can inhibit IRE1 and lead to reduced XBP1s levels [222]. Studies in endothelial cells have indicated that the IRE1 activity was necessary for maintaining the proper HIF-1α expression that was independent of the XBP1s [223]. This finding is supported by reports from other endothelial cell studies, where despite the apparent hypoxia-related IRE1 activity, the XBP1s' induction was not observed [224]. Although, this suggests that the hypoxic activation of IRE1 may serve a different role than it does during the canonical UPR, it still modulates the adaptive response to hypoxia. Further analyses will be required to decipher the significance of these findings [75,[225][226][227][228]. It is also plausible that the involvement and significance of the IRE1/XBP1s axis is cancer type-specific given that in breast cancer, the XBP1s were shown to interact with HIF-1α to cooperatively reprogram the cellular expression including the expression of glucose transporter 1 (GLUT1) and lactate dehydrogenase A (LDHA) [146,193,218]. In contrast, in colon cancer, this interaction was prevented by the hyper-activated WNT/β-catenin axis to limit the HIF-1 activity [193]. Similar mechanisms were observed in breast cancer cells during acute hypoxia, however, during prolonged hypoxia, the XBP1s induced an miR-153 expression, and this is a negative regulator of HIF-1α [215,216].
Numerous reports have indicated that HIFs are very effective in preventing ROS formation during chronic hypoxia [92,95,[243][244][245][246], and this may prevent the full activation of both the UPR and the UPRmt. Importantly, however, intermittent hypoxia (that is termed as chronic exposure of cells to cycles of hypoxia/reoxygenation) accompanies the development of the majority of solid tumors, which were also subject to persistent UPR activation [247,248]. One of the important consequences of temporal normoxia in hypoxic cells is the extensive ROS accumulation upon the reintroduction of oxygen that is also observed during hypoxia-reoxygenation injury and ischemia-reperfusion injury. This results in extensive UPR and UPRmt activation [95,177,243,. Unfortunately, however, the vast majority of hypoxia-related cancer research utilizes continuous exposure to low oxygen levels, and this may underestimate the level that is needed for the UPR activation.
PERK and IRE1, through their inhibitory effects on HIF-1α stability and transcriptional activity, could contribute the transition from HIF-1 to HIF-2 signaling in both endothelial and cancer cells that is observed during prolonged hypoxia, and this allows for a better adaptation to this insult [9,70,88,89]. Importantly, the HIF-mediated cellular adaptation to hypoxia relies on the induction of angiogenesis. This requires the elevated secretion of the proangiogenic factors and the increased expression of their specific transmembrane receptors as well as the remodeling of the extracellular space thorough the secreted enzymes. On one hand, all of these proteins modulate the TME, whereas on the other, these proteins need to mature properly, which requires that the ER homeostasis must be preserved [35,76,[275][276][277][278]. Taken together, the crosstalk between HIF signaling and UPR clearly demonstrates that the interaction between these pathways is dynamic. Furthermore, the final proadaptive or proapoptotic consequences result from the multiple networks of the temporal transcriptional and posttranscriptional signals originating from both of these pathways. The hypoxia-related involvement of the UPR is strongly oxygen concentrationdependent, and therefore, the crosstalks between these pathways in the TME will differ within the different tumor regions. Hence, cell location and kinetic approaches are needed to better understand the molecular mechanisms that are connecting the hypoxic signaling with the UPR.
The hypoxia-induced activation of the UPR can also facilitate metastasis and dormancy [279,280]. Both HIF-1 and XBP1s are reported to upregulate lysyl oxidase (LOX) in the estrogen receptor-negative breast tumors and thus promote a pre-metastatic niche formation [106,281]. Furthermore, active PERK is an important prosurvival pathway in cells that are undergoing an epithelial-to-mesenchymal transition (EMT) with an enhanced secretory capacity [282].
The hypoxia-induced UPR in cancer cells can also affect the function of the immune component of the TME and thus, limit the therapeutic approaches [45]. Both XBP1s and ATF6 reduce the surface expression of major histocompatibility complex class I (MHC-I) molecules [283], whereas PERK translational inhibition impairs their ability to present peptides to MHC-1 molecules [62]. We have demonstrated that XBP1-induced miR-346 reduces the peptides influx to the ER and MHC-I assembly [36]. All of these findings suggest that the UPR can help cancer cells to attenuate CD8 + T cell responses and thus, limit the efficiency of the immunotherapeutic approaches. Furthermore, numerous studies have indicated that cancer cells with an active UPR can drastically alter the function of the immune cells including natural killer cells, macrophages, T-cells, and myeloid cells in the TME mainly through the IRE1-XBP1s driven expression of the proinflammatory factors as well as the PERK signals. Depending on the cancer model, however, the UPR activation can support or prevent the antitumor immune responses [269,[284][285][286][287][288][289][290][291][292][293][294][295], and therefore further studies are required to better understand the UPR effects on the immune recognition in the TME in different cancer types. The complex network of molecular interaction between hypoxia and UPR is summarized in Figure 2 and Table 1.
Notably, although the hypoxia-related activation of the UPR in intratumoral immune cells has not been convincingly reported, the ROS accumulation and acidosis in the TME are known ER stressors of tumor-infiltrating leukocytes [45]. The ROS accumulation during cyclic hypoxia in solid tumors is probably underestimated, and the level of activation of the UPR in the intratumoral immune cells is unclear and therefore, further research is required to understand this process. The crosstalk between UPR and hypoxia signaling. During hypoxia, the accumulation of misfolded/unfolded proteins in ER and mitochondria activate PERK signaling, and this contributes to both pro-survival (global translational arrest and induction of pro-angiogenic genes) and apoptotic responses (induction of CHOP and inhibition of pro-angiogenic eNOS expression). Furthermore, in some models, the hypoxia-related activation of ATF6 and IRE1α contribute to pro-survival and pro-angiogenic signaling. There also appears to be cooperation between XBP1s and HIF1 in prosurvival signaling.

UPR Hypoxia Molecular Background
Ref.

General induction of UPR including BiP expression
Anoxia, acute extreme hypoxia, mild hypoxia (chronic), intermittent hypoxia Figure 2. The crosstalk between UPR and hypoxia signaling. During hypoxia, the accumulation of misfolded/unfolded proteins in ER and mitochondria activate PERK signaling, and this contributes to both pro-survival (global translational arrest and induction of pro-angiogenic genes) and apoptotic responses (induction of CHOP and inhibition of pro-angiogenic eNOS expression). Furthermore, in some models, the hypoxia-related activation of ATF6 and IRE1α contribute to pro-survival and pro-angiogenic signaling. There also appears to be cooperation between XBP1s and HIF1 in prosurvival signaling.

General induction of UPR including BiP expression
Anoxia, acute extreme hypoxia, mild hypoxia (chronic), intermittent hypoxia

UPR Activation in TME Cells Depends on Hypoxia Dynamics and Severity
The tumors are extremely heterogenous in terms of their microregions of oxygenation as well as the severity of the hypoxia that ranges from moderate oxygen deprivation to anoxia [72,296,297]. Furthermore, oxygen availably in the TME is often highly dynamic, and it is characterized by the periodic cycling of cells between various levels of oxygenation. Hence, depending on the nature of hypoxia, the cells are exposed in the TME to different levels of UPR activation as summarized below.

Anoxia and Extreme Acute Hypoxia
The tumor vasculature is often immature and lacks smooth muscle cells that along with it having high interstitial pressures, can result in drastic perfusion changes, including the temporary shutdown of vessels. This results in acute hypoxia or even anoxia of some small tumor regions (oxygen 0-0.1%) [298,299]. Notably, the tumor cells are able to survive in anoxic conditions for prolonged periods of time [74]. Such conditions result in the complete activation of UPR signaling [65,146]. This includes an increase in BiP expression that is accompanied by the rapid PERK activation and translational inhibition [188,300], and IRE1mediated XBP1 splicing [146,215,[217][218][219][220][221]. However, during the chronic exposure to acute hypoxia (above 4h), the eIF2α phosphorylation levels are a partially restored [188,300].

Moderate and Mild Hypoxia
The outpacing of a new blood supply compared to the rate of the tumor's growth and the abnormal architecture of the newly formed blood vessels often have less dramatic consequences on the oxygen delivery to the tumor regions [301,302]. Consequently, for many of the TME cells, their oxygen availability is higher, and these cells are exposed to moderate (0.1-1% oxygen) or mild hypoxia (form 1-3%). Under these conditions, the activation of the UPR requires a longer time for it to occur, and it occurs mainly during periods of chronic exposure to hypoxia. For example, the phosphorylation of eIF2α requires more than 8 h if the oxygen concentration is moderate and consequently, a translational blockage is accompanied by the mTOR inhibition [70]. Furthermore, a recent study has shown that during chronic mild hypoxia, the ER stress attenuates HIF-1 and HIF-2 signaling by promoting the degradation of their alpha subunits independent of the von Hippel-Lindau (VHL) pathway. In this case, the UPR is activated by the glycogen synthase kinase-3 beta (GSK3β) and the ubiquitin ligase FBXW1A/βTrCP [303].

Intermittent Hypoxia
Importantly, the transient changes in the blood flow, which are independent of the overall tumor oxygenation status result in large fluctuations in the tumor pO 2 levels that temporally increase the hypoxia severity. Such fluctuations usually can occur due to transient changes in the blood flow, and they are independent of the treatment or the overall tumor oxygenation status. As the blood flow changes from high to low, the proportion and severity of the hypoxia increases. Hence, the cells are exposed to continuous cycles of severe hypoxia, which is followed by reoxygenation. Additionally, these fluctuations can last from 30 min to 2 h [304,305]. Despite these relatively short period of hypoxia, this time is sufficient to switch the metabolism to the glycolytic pathway [200,306]. However, the restored oxygen availability will lead to the accumulation of ROS due to inability of the mitochondria to rapidly utilize "an extra" oxygen. This will then be accompanied by the rapid HIF-α degradation due to the reactivation of the PHDs, and the impairment of the HIF-related protection from the oxidative stress [307,308]. Hence, intermittent severe and moderate hypoxia lead to the extensive and persistent activation of the UPR and the UPRmt pathways [95,177,243,.

Conclusions
Although our current understanding of the molecular crosstalk between the UPR and hypoxia in the tumor microenvironment remains fairly limited, and presently, it is beyond any sort of therapeutic control, understanding these interactions could potentially change that. Despite our understanding of these stress pathways that has been presented in some detail in both malignant and non-malignant cells, the complexity of the activated signaling pathways remain a research barrier. A major problem is the constant variability of the different cancers as well as the complexity of the TME which often lead to apparently contradictory results. The extent of the hypoxia-related ER stress and the course of the UPR can drastically differ depending on the oxygen availability, the time of the exposure to hypoxia, as well as the type of oncogenic transformation. Furthermore, the majority of current studies often utilize two-dimensional in vitro cultures of cancer cells that are exposed to continuous hypoxia and this approach may not mimic the dynamic and cyclic conditions that are found in solid tumors.
Despite the fact that hypoxia is only one of several inducers of the UPR in the TME, solid tumors are exposed to intermittent hypoxia that results in the accumulation of high ROS levels and the complete activation of the UPR [309][310][311][312][313][314]. Furthermore, depending on the tissue, the cells often differ in their physiological oxygen needs, and consequently in their sensitivity to reoxygenation [315]. Hence, now we are witnessing the rapid development of organoid and 3-D culture models as well as single cell sequencing techniques [316,317]. Furthermore, the new approaches should evolve into more complex and relevant model systems containing both a fluctuating oxygen level component as well as the complex 3-D structure of the tumor environment.
Many of the current research models focus on understanding the hypoxia and the ER stress signaling based on steady state models utilizing a single arbitrary time of exposure. This approach does not take into account that the signaling pathways are dynamic and often changing. Furthermore, although HIFs, PERK, and IRE1 are crucial regulators of these cellular responses, their activities are accompanied by the genome-wide reprograming of the transcriptional and translational pathways. Hence, the studies focusing on analyzing the time-related profiles of the development of these signaling pathways, especially in a genome-wide context, will dramatically enhance our understanding of the crosstalk between these complex pathways. Although such approaches are very challenging, the development and increased availability of the next generation sequencing techniques, including single cell sequencing [318,319], should help to overcome these above-mentioned limitations.
A large fraction of the hypoxia-related research is solely based on use of hypoxia mimetics that function by preventing HIF-α subunit degradation in order to activate HIF signaling [320,321]. However, these compounds provide only a limited insight into the complexity of the changes in the cellular transcriptome, proteome, and metabolism that occur during hypoxia. Clearly, results that have been obtained in these models need be verified in limited oxygen conditions. Similarly, although ER homeostasis can be disturbed by many pharmacological ER stressors, depending on their mechanism of action, dosage, and time of exposure, the course of the UPR and the cell's fate will differ [141,163,322]. Taken together, although the chemical approaches to mimic the hypoxia-related activation of UPR can be used, their utility remains limited, and it should always require more physiological validations.
Nevertheless, the recent development of hypoxia-responsive nanoparticles that selectively release their cargo under hypoxic conditions in the TME [323,324] provides a perspective for the specific delivery of the UPR branches inhibitors including 4µ8C for IRE1 [325,326], ISRIB for PERK [327], or Ceapins for ATF6 [328]. This approach would provide an excellent mechanism for the selective analysis of these pathway functions in the context of the hypoxic TME.
Tumor angiogenesis relies on non-malignant endothelial cells that receive the signals from the cancer cells and are also subject to cellular insults such as hypoxia and UPR activation [46]. Furthermore, the oncogenic transformations of the malignant cells often blunt the meaning of the signaling pathways, and thus, more research in nonmalignant cells is needed to obtain proper insight into both the UPR and the cellular response to hypoxia. Although the past decade has resulted in defining the complex, novel non-coding RNA based regulatory networks that modulate both hypoxia and the UPR [36,44,89,123,163,200,290,[329][330][331][332][333][334][335], we are just to beginning to appreciate their role in modulating the TME.
Taken together, depending on the cancer type, the importance of both hypoxia and UPR signaling in the disease aggressiveness, progression, and therapy often differ. Some of these contradictions are the consequence of oncogenic transformations, whereas the others result from different experimental approaches that the researchers are using (oxygen concentration, time of hypoxic exposure, and cyclic hypoxia). Unfortunately, there is no good solution to this problem other than effectively developing more relevant cancer specific 3-D models and dynamic conditions in order to gain a better understanding of the means by which cancers avoid apoptosis or immune responses through their modulation of the UPR pathways.